Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a ...

As winter's chill lingers across Texas, propane continues to be a lifeline for many communities, keeping homes warm, businesses running, and first responders prepared. From rural towns to urban ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well ...

1 Day MNMD -3.70% DJIA -0.16% Russell 2K 0.15% Health Care/Life Sciences 0.69% ...

Pr oprietary MindMed Primary Market Research SRI ... sexual dysfunction Corporate Presentation | January 2025 MM120 Has the Potential to Redefine Treatment for Patients 7 DESIRED FUTURE STATE ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 73% phase transition success ...